An open label, single-arm, two-year extension study to evaluate the safety and tolerability of Tinlarebant in patients with Stargardt Disease. Participants have already completed the LBS-008-CT02 study protocol.
Clinical trial identifier: ACTRN12623001328662.
Principal investigator: Associate Professor Fred Chen
For more information go to https://www.anzctr.org.au/ACTRN12623001328662.aspx.
To enquire further about this study, please contact the Lions Vision Trials team on (08) 9381 0777, or email lionsvisiontrials@lei.org.au.